Program
eltrombopag
Also written as “Eltrombopag”, “SB497115” and “Eltrombopag olamine”.
Its studies are mostly in Purpura, Thrombocytopenic, Idiopathic · Thrombocytopenia · Anemia, Aplastic · Purpura · Hepatitis C, Chronic, led by 4 companies.
Drug pageEltrombopag: every studyAll 135 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKlineits history only | 290 open or running | phase 4since Jan 7, 2010 | Feb 1, 2005 | none ahead |
| Novartis | 182 open or running | phase 4since Oct 4, 2013 | Jul 10, 2006 | Apr 22, 2033phase 2 · NCT07660172 |
| Bristol-Myers Squibbits history only | 10 open or running | phase 1since Jun 20, 2023 | Jun 20, 2023 | none ahead |
| Renataits history only | 11 open or running | phase 2since Jul 6, 2024 | Jul 6, 2024 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Novartis only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 4 studies since Jul 10, 2006.
- Jun 27, 2013Phase 2 study in LeukemiaNCT01890746 · 148 enrolled · United States, Australia, Belgium and more
- Oct 4, 2013Phase 4 study in ThrombocytopeniaNCT01957176 · 22 enrolled · Belgium, China, France and more
- May 22, 2014Phase 2 study in Anemia, AplasticNCT02148133 · 21 enrolled · Japan
- Jun 5, 2014Phase 3 study in ThrombocytopeniaNCT02158936 · 356 enrolled · United States, Argentina, Australia and more
- Feb 26, 2015Phase 2 study in Anemia, AplasticNCT02404025 · 10 enrolled · Japan
- Nov 4, 2016Phase 2 study in Anemia, AplasticNCT02998645 · 54 enrolled · Brazil, Hong Kong, India and more
- Jan 12, 2017Phase 2 study in Anemia, AplasticNCT03025698 · 51 enrolled · United States, Hong Kong, Portugal and more
- May 2, 2018Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT03524612 · 105 enrolled · United States, Austria, Brazil and more
- Oct 23, 2018Phase 2 study in Poor Graft FunctionNCT03718533 · 10 enrolled · Spain
- Jun 13, 2019Phase 2 study in Anemia, AplasticNCT03988608 · 20 enrolled · China
- Mar 9, 2020Phase 2 study in Anemia, AplasticNCT04328727 · 36 enrolled · China, Japan, South Korea and more
- Apr 12, 2020Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT04346654 · 26 enrolled · Germany
- Mar 4, 2021Phase 2 study in Myelodysplastic SyndromesNCT04797000 · 36 enrolled · Japan
- Jun 15, 2026Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT07660172 · 36 planned
Ahead
- Apr 22, 2033Primary completion: phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT07660172
TargetBeta
“Thrombopoietin receptor agonist; Thrombopoietin receptor agonist”ChEMBL 37, by rule
Other programs on MPL
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| romiplostimrule | Amgen | phase 4 | 38 |
| avatrombopagrule | Eisai | phase 4 | 25 |
| hetrombopag olaminerule | Jiangsu HengRui Medicine | phase 3 | 15 |
Studies
All 18 Novartis leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07660172Purpura, Thrombocytopenic, Idiopathic | 2 | Not yet recruiting | Apr 22, 2033 | 36 |
| NCT04797000Myelodysplastic Syndromes · Japan | 2 | Active, not recruiting | Apr 26, 2025 | 36 |
| NCT04346654Purpura, Thrombocytopenic, Idiopathic · Germany | 2 | Completed | Sep 22, 2023 | 26 |
| NCT04328727Anemia, Aplastic · China, Japan, South Korea and more | 2 | Completed | Jun 10, 2022 | 36 |
| NCT03988608Anemia, Aplastic · China | 2 | Completed | Jul 16, 2021 | 20 |
| NCT03718533Poor Graft Function · Spain | 2 | Terminated | Nov 3, 2020 | 10 |
| NCT03524612Purpura, Thrombocytopenic, Idiopathic · United States, Austria, Brazil and more | 2 | Completed | Oct 22, 2021 | 105 |
| NCT03025698Anemia, Aplastic · United States, Hong Kong, Portugal and more | 2 | Completed | Apr 22, 2022 | 51 |
| NCT02998645Anemia, Aplastic · Brazil, Hong Kong, India and more | 2 | Completed | Nov 3, 2020 | 54 |
| NCT02404025Anemia, Aplastic · Japan | 2 | Completed | Jul 5, 2016 | 10 |
| NCT02158936Thrombocytopenia · United States, Argentina, Australia and more | 3 | Terminated | Apr 30, 2016 | 356 |
| NCT02148133Anemia, Aplastic · Japan | 2 | Completed | Sep 10, 2015 | 21 |
| NCT01957176Thrombocytopenia · Belgium, China, France and more | 4 | Completed | Feb 23, 2022 | 22 |
| NCT01890746Leukemia · United States, Australia, Belgium and more | 2 | Completed | Mar 13, 2015 | 148 |
| NCT02201290Purpura, Thrombocytopenic, Idiopathic · Russian Federation | 3 | Completed | Jul 4, 2017 | 9 |
| NCT01762761Purpura · China | 3 | Completed | Jun 5, 2014 | 155 |
| NCT01440374Thrombocytopenia · United States, Argentina, Belgium and more | 2 | Completed | Mar 2015 | 162 |
| NCT00351468Purpura · United States, Australia, Austria and more | 3 | Completed | Jul 2015 | 302 |
How it is read
Names in the registry
- “Eltrombopag”, 19 entries
- “eltrombopag”, 15 entries
- “SB497115”, 3 entries
- “Eltrombopag olamine”, 2 entries
- “Eltrombopag 25 MG”, 1 entry
Conditions, from the studies’ own filings
- Purpura, Thrombocytopenic, Idiopathic, 15 studies
- Thrombocytopenia, 8 studies
- Anemia, Aplastic, 6 studies
- Purpura, 5 studies
- Hepatitis C, Chronic, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.